| Popis: |
Mashael Algethami,1 Sanat Kulkarni,2 Maaz T Sadiq,3 Hiu KC Tang,4 Juliette Brownlie,1 Jennie N Jeyapalan,1 Nigel P Mongan,1 Emad A Rakha,1 Srinivasan Madhusudan1,4 1Nottingham Biodiscovery Institute, School of Medicine, University of Nottingham, University Park, Nottingham, NG7 3RD, UK; 2Department of Medicine, City Hospital, Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, B18 7QH, UK; 3Cancer Centre, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Trust, Birmingham, B15 2GW, UK; 4Department of Oncology, Nottingham University Hospitals, Nottingham, NG51PB, UKCorrespondence: Srinivasan Madhusudan, Nottingham Biodiscovery Institute, School of Medicine, University Park, University of Nottingham, Nottingham, NG7 3RD, UK, Tel +44(0)115 823 1850, Fax +44(0)115 823 1849, Email srinivasan.madhusudan@nottingham.ac.ukAbstract: Despite advances in surgery and chemotherapy, the overall outcomes for patients with advanced ovarian cancer remain poor. Although initial response rates to platinum-based chemotherapy is about 60– 80%, most patients will have recurrence and succumb to the disease. However, a DNA repair–directed precision medicine strategy has recently generated real hope in improving survival. The clinical development of PARP inhibitors has transformed lives for many patients with BRCA germline-deficient and/or platinum-sensitive epithelial ovarian cancers. Antiangiogenic agents and intraperitoneal chemotherapy approaches may also improve outcomes in patients. Moreover, evolving immunotherapeutic opportunities could also positively impact patient outcomes. Here we review the current clinical state of PARP inhibitors and other clinically viable targeted approaches in ovarian cancer.Keywords: ovarian cancer, poly-(ADP)-ribose polymerase, PARP, synthetic lethality, platinum chemotherapy |
